Eris Lifesciences Q1 FY27 earnings call

Eris Lifesciences reported a strong Q1 FY27, with Consolidated Revenue growing 13% YoY and Profit After Tax increasing by 14-15%. The Domestic Formulations Business (DBF) was a key driver, achieving a 14% revenue growth. Operating Cash Flow stood at 77% of EBITDA, and CapEx for the quarter was INR 88 crores. The effective book tax rate was 20%, down from 22.5% in Q1 last year, contributing to an EPS of INR 10.3.

While the DBF segment showed robust overall growth, specific areas like OAD and Cardiac faced challenges. Cardiac, particularly in Hypertension, is currently trailing the market, though management expects it to align with market growth within the next two quarters. OAD's reported 2% growth was clarified as an internal 6%, with the discrepancy due to a banned product (Glimisave-MV) from the previous year. New product launches, including Esaxerenone in August, are anticipated to bridge these performance gaps.

The Insulin franchise and the Semaglutide brand, SUNDAE, demonstrated strong Q1 performance, with SUNDAE capturing 20% market share by volume and 14% by value in its first quarter. The company is progressing with its Insulin Analogs pipeline, targeting Aspart's launch this calendar year and Degludec and its combination product for next year. The Bhopal manufacturing unit, critical for Biologics and Insulin production, is slated for commercialization in August 2026, with a gradual ramp-up expected by the end of Q3 FY27.

Gross margins experienced a sharp sequential decline, primarily attributed to a product mix shift towards Biologics and Insulins, which have lower gross margins (Biologics EBITDA margin as low as 20%, Insulin 30-31% vs. DBF's 74% gross margin). Raw material costs also contributed to this. Management expects Q2 gross margins to remain similar to Q1, with improvements starting in Q3 and a return to previous levels by Q4, supported by the operationalization of the Bhopal facility.

The Swiss Parenterals business recorded softer growth in Q1 due to ongoing remediation work at its facility. Management projects neutral to low single-digit growth for the full year, with potential margin compression of 100-200 basis points, though improvement is expected in Q4. The international base business remains stable, with CAPA actions on track for sites to be audit-ready by December, despite some raw material-related delays affecting goods dispatch.

The market uptake for Semaglutide has been slower than anticipated, influenced by patient resistance at the clinic level and the inherent adoption lag for chronic disease products, which typically peak in the third year. Despite this, management remains confident in the drug's long-term potential and is not considering price reductions, focusing instead on adoption. The launch of the Wegovy Gx version in July/August 2026 is expected to further boost its market presence.

Eris Lifesciences is prioritizing investments in manufacturing facilities and technology, particularly at its Bhopal unit, over acquisitions for the current and next fiscal year. This strategic focus aims to strengthen the company's backend capabilities and support the growth of new-age products like Biologics and Insulins. This shift in portfolio and manufacturing is expected to drive the company towards a 'top-tier of growth' in the coming years.